Menu Back toRegulatory, Industry, Patient, and Academic Perspectives on Machine Learning in Clinical Trials
Don't Miss Out!
Get your weekly Breakfast Briefing eNewsletter, filled with news, trends, and vital information from DIA!
DIA 2021 Global Annual Meeting
Regulatory, Industry, Patient, and Academic Perspectives on Machine Learning in Clinical Trials
Stuart Michael Bailey, PhD
- Vice President, Head of Analytics and Data Sciences
- Biogen, United States
Machine / deep learning is being applied in an increasing number of industries, and biopharma is no exception. This session will examine regulator, patient, industry, and technical perspectives on machine learning applications in drug development
Learning Objective : Identify opportunities to prospectively integrate machine learning approaches and expertise within the modern drug development process; Evaluate challenges in the application of machine learning approaches in clinical trials and assessing benefit/risk; Distinguish between the use and value of historical, contextual, synthetic, and real-world data.
John Zhong, PhD
- Vice President, Head of Biometrics
- REGENXBIO, Inc., United States
EMA Update on Machine Learning in Clinical Trials
Florence Butlen-Ducuing, MD, PhD, MS
- Senior Scientific Officer, Office of Therapies for Neurological and Psychiatric
- European Medicines Agency, Netherlands
Philip John Green
- Steering Committee Patient Representative
- CTTI, United States